Genetic causes of recurrent pregnancy loss
Project/Area Number |
24592478
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Nagoya City University |
Principal Investigator |
Sugiura Mayumi 名古屋市立大学, 医学(系)研究科(研究院), 教授 (30264740)
|
Project Period (FY) |
2012-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
Keywords | 不育症 / 習慣流産 / 凝固第XII因子 / 凝固第V因子 / プロテインS / ループスアンチコアグラント / 抗リン脂質抗体 / 不育症易罹患性遺伝子 / Recurrent Pregnancy Loss / Recurrent Miscarriage / Coagulation Factor XII / Annexin A5 / Protein S / Coagulation Factor V / APS / PGD / recurrent pregnancy loss / recurrent miscarriege / Factor XII / Factor V Nara / R2 haplotype / PGD / recurrent miscarriage |
Outline of Final Research Achievements |
Six kinds of SNPs of ANXA5, CT genotype of coagulation factor XII (FXII) and GT and TT genotype of Ser156Ser of FV were found to be risk factors for recurrent pregnancy loss (RPL). The frequency of protein S (PS) Tokushima in patients was similar to that in controls. No case of Nara mutation and Hong Kong mutation were found in both patients and controls. There was no difference of subsequent live birth rate between with and without risk alleles of ANXA5, FXII, FV and PS Tokushima. There was no difference of subsequent live birth rate between low and normal levels of FXII activity, PS antigen, PS activity and PS specific activity after excluding cases with RPL caused by abnormal embryonic karyotype. We found CT genotype of FXII as a risk factor for RPL at the first time. However, the genotyping of these risk alleles and testing for FXII activity and PS measurement were not necessary because of absence of clinical benefit.
|
Report
(5 results)
Research Products
(98 results)